RN1871

RN1871 is a small interfering RNA (siRNA) drug developed to target and silence angiotensinogen (AGT) mRNA expression in the liver. By inhibiting AGT production, it disrupts the Renin-Angiotensin-Aldosterone System (RAAS), a key pathway involved in blood pressure regulation. Overactivation of RAAS is closely linked to hypertension progression. Preclinical studies have shown that RN1871 provides long-lasting blood pressure control with sustained efficacy and less frequent dosing, offering a promising new therapeutic option for hypertension management[1][2][6]. The drug is being advanced into Phase I clinical trials to evaluate its safety, pharmacokinetics, and preliminary efficacy in humans[2].